An unusual origin story
PT-141, known in the pharmaceutical literature as bremelanotide, is a cyclic heptapeptide derived from Melanotan 2. During early Melanotan 2 studies, researchers observed effects mediated through central melanocortin receptors that were unrelated to pigmentation — an observation that redirected an entire development programme. PT-141 was the result: a molecule refined to act on melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the central nervous system.
Where the research stands
- Receptor pharmacology — PT-141 is a standard reference agonist in MC4R binding assays, one of the most studied receptors in energy-balance and behavioural neuroscience.
- Clinical development — unusually for compounds in the research-peptide world, bremelanotide completed full FDA clinical trials and was approved in the US in 2019 under the brand name Vyleesi for a specific indication. This gives researchers a rare body of published human pharmacokinetic and safety data to draw on.
- Central vs peripheral action — studies contrast PT-141's CNS-mediated mechanism with peripherally acting comparators, a distinction that features heavily in the melanocortin literature.
Relationship to the melanotan family
PT-141 shares its lineage with Melanotan 2 and, more distantly, Melanotan 1. Our Melanotan 1 vs Melanotan 2 comparison maps out the family tree. The key distinction: PT-141 lacks the pigmentation-driving MC1R emphasis of its ancestors.
For laboratory buyers
PT-141 from BioSupply UK is supplied lyophilised at ≥99% verified purity with a batch Certificate of Analysis. In the UK it is not a licensed medicine, and vials are supplied for laboratory research only.
Summary
PT-141 is one of the few research-catalogue peptides with a completed regulatory journey behind it in another jurisdiction — which makes its literature unusually rich, even though the UK research-supply context remains unchanged: laboratory use only.
All products mentioned are supplied strictly for laboratory research purposes only and are not intended for human consumption, diagnosis, or treatment. Nothing in this article constitutes medical advice.